Short Interest in UCB SA (OTCMKTS:UCBJY) Increases By 65.6%

UCB SA (OTCMKTS:UCBJY) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 25,500 shares, a growth of 65.6% from the May 31st total of 15,400 shares. Based on an average trading volume of 25,700 shares, the short-interest ratio is presently 1.0 days.

UCB Price Performance

UCB stock opened at $74.13 on Friday. UCB has a twelve month low of $34.85 and a twelve month high of $74.63. The firm has a 50 day moving average price of $69.11 and a 200-day moving average price of $58.09.

UCB Cuts Dividend

The business also recently announced a dividend, which was paid on Wednesday, May 15th. Stockholders of record on Monday, April 29th were given a dividend of $0.4574 per share. This represents a dividend yield of 0.71%. The ex-dividend date was Friday, April 26th. UCB’s dividend payout ratio is currently 46.55%.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.